InvestorsObserver
×
News Home

Should Genocea Biosciences Inc (GNCA) Stock Be in Your Portfolio?

Tuesday, February 16, 2021 11:34 AM | InvestorsObserver Analysts

Mentioned in this article

Should Genocea Biosciences Inc (GNCA) Stock Be in Your Portfolio?

Genocea Biosciences Inc (GNCA) is near the top in its sector according to InvestorsObserver.

GNCA gets an overall rating of 24. That means it scores higher than 24% of stocks.

Genocea Biosciences Inc gets a 76 rank in the Healthcare sector. Healthcare is number 1 out of 11 sectors.

Overall Score - 24
GNCA has an Overall Score of 24. Find out what this means to you and get the rest of the rankings on GNCA!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 24 would rank higher than 24 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in the healthcare sector with relative ease.

These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Genocea Biosciences Inc Stock Today?

Genocea Biosciences Inc (GNCA) stock has gained 7.96% while the S&P 500 is lower by -0.09% as of 11:31 AM on Tuesday, Feb 16. GNCA is higher by $0.27 from the previous closing price of $3.39 on volume of 798,351 shares. Over the past year the S&P 500 is up 16.65% while GNCA is higher by 72.64%. GNCA lost -$0.98 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Genocea Biosciences Inc (GNCA) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App